Why does NAFLD predict type 2 diabetes?

Current Diabetes Reports

Volumn 11, Issue 3, 2011, Pages 167-172

  Lattuada, Guido ^a,b   Ragogna, Francesca ^b   Perseghin, Gianluca ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Fatty liver; FFA; Magnetic resonance spectroscopy; Nonalcoholic fatty liver disease (NAFLD)

Indexed keywords

ALANINE AMINOTRANSFERASE; CORTICOSTEROID; GAMMA GLUTAMYLTRANSFERASE; IMMUNOSUPPRESSIVE AGENT; INSULIN; INSULIN RECEPTOR; LEPTIN;

CLINICAL FEATURE; DISEASE ASSOCIATION; GENE EXPRESSION PROFILING; HUMAN; INFLAMMATORY INFILTRATE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER CIRRHOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PANCREAS ISLET BETA CELL; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; RISK FACTOR;

ANIMALS; DIABETES MELLITUS, TYPE 2; FATTY LIVER; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 79955925904     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-011-0190-2     Document Type: Review

References (51)

1. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844-50. (Pubitemid 33641605)
2. Biddinger SB, Kahn CR. From mice to men: insights into the insulin resistance syndromes. Annu Rev Physiol. 2006;68:123-58.
3. Glykosurie und Diabetes durch experimentelle Insulte und Krankheiten der Leber. In Naunyn B. Der Diabetes Mellitus. Wien: A. Holder, 1898:38-49.
4. Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver disease. Lancet. 1967;2:1051-6.
5. Conn HO, Schreiber W, Elkington SG, Johnson TR. Cirrhosis and diabetes. Increased incidence of diabetes in patients with Laennec's cirrhosis. I. Am J Dig Dis. 1969;14:837-52.
6. Conn HO, Schreiber W, Elkington SG. Cirrhosis and diabetes. Association of impaired glucose tolerance with portal-systemic shunting in Laennec's cirrhosis. Am J Dig Dis. 1971;16:227-39.
7. Gentile S, Loguercio C, Marmo R, Carbone L, Del Vecchio-Blanco C. Incidence of altered glucose tolerance in liver cirrhosis. Diabetes Res Clin Pract. 1993;22:37-44. (Pubitemid 24040561)
8. Perseghin G, Mazzaferro V, Piceni Sereni L, Regalia E, Benedini S, Bazzigaluppi E, et al. Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation. Hepatology. 2000;31:694-703. (Pubitemid 30118638)
9. Petrides AS, De Fronzo RA. Glucose metabolism in cirrhosis: a review with some perspectives for the future. Diabetes Metab Rev. 1989;5:691-709. (Pubitemid 20097247)
10. Petrides AS, Groop LC, Riely CA, De Fronzo RA. Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis. J Clin Invest. 1991;88:561-70.
11. Selberg O, Burchert W, v.d.Hoff J, Meyer GJ, Hundeshagen H, Radoch E, et al. Insulin resistance in liver cirrhosis. Positronemission tomography scan analysis of skeletal muscle glucose metabolism. J Clin Invest. 1993;91:1897-902. (Pubitemid 23141457)
12. Perseghin G, Regalia E, Battezzati A, Vergani S, Pulvirenti A, Terruzzi I, et al. Regulation of glucose homeostasis in humans with a denervated liver. J Clin Invest. 1997;100:931-41. (Pubitemid 27371712)
13. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity an normal men. J Clin Endocrinol Metab. 2002;87:3023-8. (Pubitemid 34816338)
14. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, et al. Insulin resistance in non-diabetic patients with nonalcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48:634-42. (Pubitemid 40591217)
15. Pietilainen KH, Rissanen A, Kaprio J, Makimattila S, Hakkinen A-M, Westerbacka J, et al. Acquired obesity is associated with increased liver fat, intra-abdominal fat, and insulin resistance in young adult monozygotic twins. Am J Physiol. 2005;288:E768-74.
16. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005;54:603-8. (Pubitemid 40322060)
17. Ryysy L, Häkkinen A-M, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes. 2000;49:749-58. (Pubitemid 30339990)
18. Hwang J-H, Stein DT, Barzilai N, Cui M-H, Tonelli J, Kishore P, et al. Increased intrahepatic is associated with peripheral insulin resistance: in vivo MR imaging and spectroscopy. Am J Physiol Endocrinol Metab. 2007;293:E1663-9.
19. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, Balletshofer B, Machicao F, Fritsche A, Haring H-U. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 68: 1609-1616, 2008. In this work it is demonstrated that a metabolically benign obesity that is not accompanied by insulin resistance and early atherosclerosis exists in humans and that ectopic fat in the liver may be more important than visceral fat and other metabolic factors in the determination of such a beneficial phenotype in obesity.
20. Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology. 2007;133:496-506. (Pubitemid 47187337)
21. Perseghin G, Bonfanti R, Magni S, Lattuada G, De Cobelli F, Canu T, et al. Insulin resistance and whole body energy homeostasis in obese adolescents with fatty liver disease. Am J Physiol Endocrinol Metab. 2006;291:E697-703.
22. Petersen KF, Arioglu Oral E, Dufour S, Befroy D, Ariyan C, Yu C, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002;109:1345-50. (Pubitemid 34546899)
23. Kim SP, Ellmerer M, Van Citters GW, Bergman RN. Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate-fat diet in the dog. Diabetes. 2003;52:2453-60. (Pubitemid 37210532)
24. An J, Muoio DM, Shiota M, Fujimoto Y, Cline GW, Shulman GI, et al. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver, and whole animal insulin resistance. Nat Med. 2004;10:268-74.
25. Nagle CA, An J, Shiota M, Torres TP, Cline GW, Liu Z-X, et al. Hepatic Overexpression of glycerol-sn-3-phosphate acyltransferase 1 in rats causes insulin resistance. J Biol Chem. 2007;282:14807-15. (Pubitemid 47093356)
26. Lautt WW. The HISS story overview: a novel hepatic neurohumoral regulation of peripheral insulin sensitivity in health and diabetes. Can J Physiol Pharmacol. 1999;77:553-62.
27. Petersen KF, Tygstrup N. A liver factor increasing glucose uptake in rat hindquarters. J Hepatol. 1994;20:461-5. (Pubitemid 24146358)
28. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450-5. (Pubitemid 29528333)
29. Perseghin G, Caumo A, Lattuada G, De Cobelli F, Ntali G, Esposito A, et al. Elevated fasting plasma C-peptide occurs in non-diabetic individuals with fatty liver irrespectively of insulin resistance. Diabet Med. 2009;26:847-54.
30. Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab. 2007;92:3490-7. (Pubitemid 47435325)
31. Tushuizen ME, Bunck MC, Pouwels PJW, Bontemps S, Mari A, Diamant M. Lack of association of liver fat with model parameters of beta-cell function in men with impaired glucose tolerance and type 2 diabetes. Eur J Endocrinol. 2008;159:251-7.
32. Saisho Y, Butler AE, Meier JJ, Monchamp T, Allen-Auerbach M, Rizza RA, et al. Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes. Clin Anat. 2007;20:933-42. (Pubitemid 350074312)
33. Tushuizen ME, Bunck MC, Pouwels PJ, Bontemps S, van Waesberghe JH, Schindhelm RK, et al. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. Diabetes Care. 2007;30:2916-21. (Pubitemid 350083144)
34. van der Zijl NJ, Goossens GH, Moors CC, van Raalte DH, Muskiet MH, Pouwels PJ, et al. Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on {beta}-cell function in individuals with impaired glucose metabolism. J Clin Endocrinol Metab. 2011;96:459-67.
35. Kotronen A, Vehkavaara S, Seppälä-Lindroos A, Bergholm R, Yki-Jarvinen H. Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab. 2007;293:E1709-15.
36. Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S, Yki-Järvinen H. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology. 2008;135:122-30. (Pubitemid 351899009)
37. Battezzati A, Terruzzi I, Perseghin G, Bianchi E, Di Carlo V, Pozza G, et al. Defective insulin action on protein and glucose metabolism during chronic hyperinsulinemia in subjects with benign insulinoma. Diabetes. 1995;44:837-44.
38. Petrides AS, Stanley T, Matthews DE, Vogt C, Bush AJ, Lambeth A. Insulin resistance in cirrhosis: prolonged reduction of hyperinsulinemia normalizes insulin sensitivity. Hepatology. 1998;28:141-9. (Pubitemid 28299995)
39. Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A, et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes. 2003;52:2882-7. (Pubitemid 37466856)
40. Westerbacka J, Kolak M, Kiviluoto T, Arkkila P, Siren J, Hamsten A, et al. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes. 2007;56:2759-65. (Pubitemid 350044919)
41. Perseghin G, Petersen KF, Shulman GI. Cellular mechanisms of insulin resistance; potential links with inflammation. Int J Obes. 2003;27:S6-S11. (Pubitemid 38019180)
42. Cai D, Yuan M, Frantz FD, Melendez PA, Hansen L, Lee J, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005;11:183-90. (Pubitemid 40321354)
43. André P, Balkau B, Born C, Royer B, Wilpart E, Charles MA, et al. Hepatic markers and development of type 2 diabetes in middle aged men and women: a three-year follow-up study. The D.E.S.I. R. Study. (Data from an Epidemiological Study on the Insulin Resistance syndrome). Diabetes Metab. 2005;31:542-50.
44. Fraser A, Thinggaard M, Christensen K, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase (GGT) and allcause mortality: results from a population-based Danish twins study alanine aminotransferase, GGT and mortality in elderly twins. Liver Int. 2009;29:1494-9.
45. Sattar N, Scherbakova O, Ford I, O'Reilly D, St J, Stanley A, et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of scotland coronary prevention study. Diabetes. 2004;53:2855-60. (Pubitemid 39425910)
46. Shlomai A, Kariv R, Leshno M, Beth-Or A, Sheinberg B, Halpern Z. Large-scale population analysis reveals an extremely low threshold for "non-healthy" alanine aminotransferase that predicts diabetes mellitus. J Gastroenterol Hepatol. 2010;25:1687-91.
47. Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of type 2 diabetes in Korean adults. Diabet Med. 2008;25:476-781.
48. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol. 2007;22:1086-91. (Pubitemid 47019857)
49. Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2007;30:2940-4. (Pubitemid 350083148)
50. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
51. Balkau B, Lange C, Vol S, Fumeron F, Bonnet F for Group Study D.E.S.I.R. Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterology 10:56, 2010. This is a very recent study showing how surrogate algorithms of fatty liver may actually predict incident type 2 diabetes.